The data from this study are available upon request. For this study we requested data from the PredictND consortium. The data-sharing agreement of the PredictND consortium however allows us use of data for this specific project only. The data underlying the results presented in the study are available from the PredictND-board; <team@predictnd.eu>.

Introduction {#sec005}
============

An accurate and timely clinical diagnosis of Alzheimer's disease (AD) is important both for care and research \[[@pone.0226784.ref001]\]. Over the last decade the field has moved from a purely clinical concept to a more biological definition of AD \[[@pone.0226784.ref002]\]. The development of CSF biomarkers has played a pivotal role in this paradigm-shift, enabling accurate detection of AD pathology in vivo \[[@pone.0226784.ref003]\]. The current diagnostic criteria emphasize the use of these biomarkers in suspected AD \[[@pone.0226784.ref002], [@pone.0226784.ref004]\].

Diagnostic guidelines do not specify which patients should receive CSF testing however, and as a result there is a large practice variation \[[@pone.0226784.ref005]\]. Recently, a set of criteria for the use of CSF has been published, mirroring the appropriate use criteria (AUC) for amyloid PET, but these are still rather difficult to translate to clinical practice \[[@pone.0226784.ref006]\]. First, they are phrased in rather general terms, e.g. 'CSF biomarkers can be ordered for all patients with suspected underlying AD pathology', which carries the risk of performing CSF unnecessarily. In addition, the AUC for CSF state that there 'should be a determination of how CSF biomarkers might contribute to the diagnosis and clinical decision making', but it is not self-evident how this should be done. Furthermore, ordering of CSF should also depend on 'the confidence of the clinician in the diagnosis' \[[@pone.0226784.ref006]\].

Data-driven support tools could be helpful to answer the question 'for which patient should CSF biomarkers be measured?' before embarking on actual testing. By using simulated positive (AD like) or negative (normal) CSF biomarker profiles for a specific patient added to their priori clinical information, such a tool could inform the clinician on how the knowledge of CSF biomarkers would impact (confidence in a) diagnosis \[[@pone.0226784.ref007]\].

The Disease state index (DSI) classifier is a clinical decision support system (CDSS) which supports the differential diagnosis of several types of dementia by combining and weighing all available information, including cognitive tests, automated MRI features and CSF biomarkers \[[@pone.0226784.ref008]\]. This multi-class classifier has previously shown to be able to differentiate between several types of dementia \[[@pone.0226784.ref009], [@pone.0226784.ref010]\]. The DSI classifier can achieve high probability of correct diagnosis even without CSF biomarkers, by using an optimal combination of tests \[[@pone.0226784.ref011], [@pone.0226784.ref012]\].

In this work, we took the functionality of our CDSS as an input to predict who would benefit from CSF testing. More specifically, we tested whether the CDSS may help to answer the following question: if a clinician already has information on neuropsychological tests and MRI brain, would additional CSF testing contribute significantly to a more accurate diagnosis? We thus aimed to evaluate how a computer-based tool can help in selecting those patients by using a data-driven approach and simulated CSF outcome.

Methods {#sec006}
=======

Subjects {#sec007}
--------

We included 535 subjects from three memory clinics, as part of the PredictND project \[[@pone.0226784.ref013]\]: 463 subjects from the Amsterdam Dementia Cohort from the Alzheimer center of the Amsterdam UMC (the Netherlands) \[[@pone.0226784.ref014], [@pone.0226784.ref015]\]), 50 subjects from the Danish Dementia Research Centre at Copenhagen University Hospital, Rigshospitalet (Denmark) and 22 subjects from the Neurocenter at Kuopio University Hospital (Finland). The pooled cohort consisted of subjects with the following diagnosis: 286 (53%) AD, 82 (13%) frontotemporal dementia (FTD), 28 (5%) vascular dementia (VaD) and 139 (26%) controls with subjective cognitive decline (SCD). Subjects were eligible for inclusion if both CSF and brain MRI results were available.

All subjects had received a standardized work-up, including medical history, physical, neurological and neuropsychological assessment, MRI, laboratory tests and CSF. Subjects were diagnosed as SCD when the cognitive complaints could not be confirmed by cognitive testing and criteria for mild cognitive impairment (MCI) or dementia were not met. Probable AD was diagnosed using the core clinical criteria of the NIA-AA for AD dementia \[[@pone.0226784.ref004]\]. Probable FTD (including the behavioural variant of FTD, progressive non-fluent aphasia and semantic dementia) was diagnosed using the criteria from Rasckovsky and Gorno-Tempini, respectively \[[@pone.0226784.ref016], [@pone.0226784.ref017]\]. VaD was diagnosed using the NINDS-AIREN criteria \[[@pone.0226784.ref018]\]. The local Medical Ethical Committee reviewed and approved the study, including its consent procedure, in accordance with the declaration of Helsinki. Capacity to consent was determined by the clinician, who performed the work-up. All patients provided written informed consent for their data to be used for research purposes.

Neuropsychology {#sec008}
---------------

Cognitive functions were assessed with a brief standardized test battery including widely used tests. We used the Mini-Mental State Examination (MMSE) for global cognitive functioning \[[@pone.0226784.ref019]\]. For memory we included the Rey auditory verbal learning task (RAVLT) \[[@pone.0226784.ref020]\]. To measure mental speed and executive functioning we used Trail Making Test A and B (TMT-A, TMT-B) \[[@pone.0226784.ref021]\]. Language and executive functioning were tested by category fluency (animals) \[[@pone.0226784.ref022]\]. For behavioral symptoms we used the Neuropsychiatric Inventory (NPI) \[[@pone.0226784.ref023]\]. Missing data ranged from n = 3 (1%) (MMSE) to n = 126 (24%) (TMT-B).

Cerebrospinal fluid biomarkers {#sec009}
------------------------------

CSF beta amyloid 1--42 (AB42), total tau and tau phosphorylated at threonine 181 (p-tau) were measured with commercially available ELISA tests (Innotest, Fujirebio, Ghent, Belgium) locally according to standard procedures. Raw data values were used for analysis. Analysis showed comparable values between the centers and hence no further correction was performed.

APOE genotype {#sec010}
-------------

Apolipoprotein-E (APOE) genotyping were performed locally in each center. Patients were dichotomized into APOE e4 carriers (hetero- and homozygous) and non-carriers. APOE data were available in 472 (88%) subjects.

Imaging markers {#sec011}
---------------

MRI images were acquired using 1.5 T or 3 T scanners. The voxel size varied between 0.5--1.1 × 0.5--1.1 × 0.9--2.2 mm for T1 images and 0.4--1.3 × 0.4--1.2 x 0.6--6.5 mm for FLAIR images. We extracted five imaging markers using the cNeuro^®^ cMRI quantification tool: 1) computed medial temporal lobe atrophy (cMTA), 2) computed global cortical atrophy (cGCA), 3) AD similarity scale, 4) Anterior Posterior index and 5) white matter hyperintensities (WMH). First, we automatically computed the MTA and GCA scores \[[@pone.0226784.ref024], [@pone.0226784.ref025]\]. To do so, we defined volumes of brain structures from T1 image segmentations produced by a multi-atlas segmentation algorithm \[[@pone.0226784.ref009], [@pone.0226784.ref026]\]. The cMTA was defined from the volumes of the hippocampi and inferior lateral ventricles separately for left and right. In addition to volumetry, voxel-based morphometry (VBM) \[[@pone.0226784.ref027]\] was applied to compute gray matter concentrations which were used to define the cGCA. For the AD similarity scale, the region of interest (ROI) in the patient image was represented as a linear combination of the corresponding ROIs from a database of previously diagnosed patients \[[@pone.0226784.ref028], [@pone.0226784.ref017]\]. A ROI-based grading imaging marker was defined as the share of the weights from the linear model having the diagnostic label AD while using the hippocampus area as a ROI. The Anterior Posterior index is a specific measure for characterizing fronto-temporal atrophy, a well-known hallmark in FTD. API measures the relative volume of the cortex in the fronto-temporal and parieto-occipital regions. \[[@pone.0226784.ref029]\]. In addition, we automatically extracted the volume of WMH from FLAIR images \[[@pone.0226784.ref009], [@pone.0226784.ref030]\]. All imaging markers are corrected for head size \[[@pone.0226784.ref031]\] and for age and sex \[[@pone.0226784.ref032]\].

Disease State Index classifier {#sec012}
------------------------------

The Disease State Index (DSI) classifier is a simple supervised and data-driven machine learning method that compares different diagnostic groups with each other; controls, AD, FTD and VaD in this work \[[@pone.0226784.ref008], [@pone.0226784.ref013]\]. DSI is a continuous value between zero and one, measuring the similarity of all patient data to diagnostic groups defined \[[@pone.0226784.ref008]\]. For each single test result from cognitive tests, APOE, imaging or CSF, a reference dataset determines a fitness function f(x) = FN(x)/(FN(x)+FP(x)) where FN and FP are false negative and positive rates, respectively, when using x as a cut-off to classify patients into two diagnostic groups. Then, this function is used to compute fitness value between zero and one to each test result of the patient. 2) The 'relevance' of each test result is defined as sensitivity+specificity-1 from the reference dataset. 3) DSI is calculated by averaging all fitness values by weighting them with their relevance. This process is repeated for each pairwise comparison (controls-AD, controls-FTD, controls-VaD, AD-FTD, AD-VaD, VaD-FTD). The total DSI for each diagnostic group is the average over all pairwise comparisons, e.g. AD-controls, AD-FTD and AD-VaD for AD. All variables are corrected for age and sex \[[@pone.0226784.ref032]\]. Due to the design of DSI, there is no need to impute data or exclude cases with incomplete data, as only available data are used \[[@pone.0226784.ref010]\].

Probability of correct class {#sec013}
----------------------------

A high total DSI value or a big difference in DSI values between the two most similar diagnostic groups (first and second DSI) provides more confidence for making a diagnosis than a low value or a small difference. Therefore, we define a new measure, probability of correct class (PCC), which estimates the probability that the suggested diagnosis for a patient is correct, when compared to the clinical diagnosis (ground truth). If the highest DSI value is 0.75 and the second highest is 0.67 for the patient being studied, PCC measures the share of correctly classified cases in the reference database having DSI close to 0.75 and difference close to 0.75--0.67 = 0.08. In other words, PCC estimates (personalized) confidence in classification, i.e., classification accuracy for this very patient. In clinical practice the clinician can adjust the applied PCC cutoff depending on the required accuracy. In this study, patients were considered as having a diagnosis with sufficient accuracy if PCC was at least 0.80. For comparison we performed a sensitivity analysis and repeated our analyses for different PCC cut-offs. Details on the definition and calculation of PCC can be found in the supplement file ([S1 File](#pone.0226784.s001){ref-type="supplementary-material"}).

Simulated CSF to guide clinical decision making {#sec014}
-----------------------------------------------

In our search for a scenario with the largest proportion of patients diagnosed with high confidence (PCC≥0.80), against the smallest proportion of CSF tested, we applied four scenarios:

-   Scenario A ("computerized decision support"): We performed CSF only when predicted to be useful ([Fig 1A](#pone.0226784.g001){ref-type="fig"}). This was modelled using a stepwise approach: first, patients diagnosed with PCC≥0.80 based on neuropsychology, MRI and APOE were regarded as clear cases and no CSF was ordered (step one). For the remaining patients with a PCC\<0.80, we simulated adding CSF biomarkers; PCC was recomputed after adding positive (age- and sex-normalized median AB42, tau and p-tau values of AD group) and negative (age- and sex-normalized median AB42, tau and p-tau values of SCD group) CSF values (step two) \[[@pone.0226784.ref032]\]. If either of the resulting simulated PCC values reached the cut-off of≥0.80, actual CSF values were added, and DSI and PCC calculated using these real values (step three).

-   Scenario B ("No CSF"): We calculated DSI and PPC for each patient using neuropsychology, MRI and APOE, excluding CSF ([Fig 1B](#pone.0226784.g001){ref-type="fig"}).

-   Scenario C ("AUC"): We performed CSF based on the AUC criteria ([Fig 1C](#pone.0226784.g001){ref-type="fig"}), which state that CSF biomarkers can be applied to all patients with suspected underlying AD pathology \[[@pone.0226784.ref006]\]. We operationalized this as a DSI for AD \>0.6. In all patients with a DSI for AD \>0.6, we then calculated PCC adding CSF (step two). For patients with a DSI for AD ≤0.6, no CSF was added and DSI and PCC were calculated using only neuropsychology, MRI and APOE.

-   Scenario D ("All CSF"): We performed CSF in all patients ([Fig 1D](#pone.0226784.g001){ref-type="fig"}). We calculated DSI and PCC for each patient using neuropsychology, MRI, APOE and CSF.

![Flow chart for the four diagnostic scenarios.\
AUC: appropriate use criteria according to \[[@pone.0226784.ref033]\], operationalized as a DSI for AD \>0.6, PCC: probability of correct class, NP: neuropsychology, MRI: magnetic resonance imaging, CSF: cerebrospinal fluid biomarkers, Sim.: simulate, FU: follow-up. Numbers in circles denote groups described in section 3.3 and [Table 3](#pone.0226784.t003){ref-type="table"}.](pone.0226784.g001){#pone.0226784.g001}

Statistical analyses {#sec015}
--------------------

We used a two-sample test of proportion to test differences in proportion of patients 1) with CSF tested, and 2) diagnosed with sufficient confidence (PCC≥0.80), between the computerized decision support and the other scenarios \[[@pone.0226784.ref034]\]. We compared the different groups derived from the computerized decision support (scenario A), using Analysis of Variance (ANOVA).

In an additional sensitivity analysis, we visualized the share of patients diagnosed (percentage of patients above PCC cutoff) and the share of patients with CSF measurement for a range of PCC cut-offs (0.5--1.0), and calculated the classification accuracy of the diagnosed patients. This was done for the four diagnostic scenarios: A) the computerized decision support, B) No CSF, C) AUC, and D) All CSF.

Statistical analyses were performed using STATA version 14.1 and R version 3.5.3. A MATLAB toolbox created by \[[@pone.0226784.ref035]\] was used in the DSI analyses. The analyses were performed in MATLAB version R2015b (MathWorks, Natick, MA, USA).

Results {#sec016}
=======

Baseline characteristics {#sec017}
------------------------

Overall mean age was 65±8 and 262 (49%) were females. Details on cognitive tests, MRI markers and CSF results and by group can be found in [Table 1](#pone.0226784.t001){ref-type="table"}.

10.1371/journal.pone.0226784.t001

###### Baseline characteristics according to baseline diagnosis.

![](pone.0226784.t001){#pone.0226784.t001g}

                                      n =   Control n = 139   AD n = 286   FTD n = 82   VaD n = 28
  ----------------------------------- ----- ----------------- ------------ ------------ ------------
  **Female, n (%)**                   535   60 (43)           158 (55)     36 (44)      8 (29)
  **Age, in years**                   535   62 ±8             67 ±8        63 ±6        70 ±8
  **APOE e4 carrier, n (%)**          472   52 (42)           165 (65)     25 (34)      10 (48)
  ***Neuropsychology***                                                                 
  **MMSE**                            532   28 ±1             21 ±5        24 ±4        24±4
  **RAVLT, learning**                 506   42 ±9             22 ±8        28 ±8        24 ±8
  **RAVLT, recall**                   506   9 ±3              2 ±2         4 ±3         4 ±3
  **TMT-A, in seconds**               515   37 ±20            79 ±54       57 ±36       96 ±57
  **TMT-B, in seconds**               409   85 ±39            193 ±80      155 ±77      220 ±86
  **Animal fluency**                  519   22 ±5             13 ±5        12 ±7        11 ±4
  **NPI, total score**                445   7 ±9              11 ±11       22 ±17       16 ±10
  ***MRI***                                                                             
  **cMTA right**                      535   0.3 ±0.5          1.4 ±0.8     1.6 ±1.2     1.5 ±1.0
  **cMTA left**                       535   0.3 ±0.5          1.5 ±0.9     2.0 ±1.4     1.5 ±1.2
  **cGCA**                            535   0.3 ±0.5          1.2 ±0.8     1.3 ±0.8     1.4 ±0.7
  **WMH, ml**                         535   2.9 ±4.7          6.6 ±9.9     3.6 ±7.7     44.5 ±29.6
  **AD similarity scale**             535   0.4 ±0.1          0.6 ±0.1     0.4 ±0.1     0.6 ±0.1
  **Anterior Posterior index**        535   0.1 ±0.7          0.1 ±1.2     -2.1 ±1.7    0.1 ±1.1
  ***CSF***                                                                             
  **AB42, pg/ml**                     535   928 ±280          535 ±183     914 ±250     704 ±252
  **Total tau, pg/ml**                535   322 ±208          693 ±405     337 ±140     308 ±162
  **P- tau, pg/ml**                   535   52 ±24            86 ±39       45 ±18       43 ±18
  **AUC+ (DSI for AD\>0.6), n (%)**   535   5 (4)             250 (87)     31 (38)      9 (32)

AD: Alzheimer´s disease, FTD: Frontotemporal dementia, VAD: Vascular dementia, MMSE: Mini-Mental state Examination, RAVLT: Rey Auditory Verbal Learning Test, TMT: Trail Making Test, NPI: Neuropsychiatric Inventory score, cMTA: computed medial temporal lobe atrophy scale (0--4), derived from volume of hippocampus and volume of inferor lateral ventricle, cGCA: computed global cortical atrophy scale (0--3), derived from concentration of cortical grey matter using voxel based morphometry, WMH: volume of white matter hyperintensities, AD similarity scale:based on hippocampus ROI, Anterior posterior index: weighted ratio of volumes of the frontal/temporal lobes and parietal/occipital lobes. MRI volumes are adjusted for head size, AB42: beta amyloid 1--42; p-tau: tau phosphorylated at threonine 181. AUC+: number of patients fulfilling appropriate use criteria according to \[[@pone.0226784.ref033]\], operationalized as a DSI for AD \>0.6.

Data are presented as mean ± SD, unless otherwise specified.

Contribution of CSF to diagnosis {#sec018}
--------------------------------

To evaluate in which patients the knowledge of CSF changed the confidence in the diagnosis, we examined four diagnostic scenarios, as shown in [Fig 1](#pone.0226784.g001){ref-type="fig"}.

In the computerized decision support ([Fig 1A](#pone.0226784.g001){ref-type="fig"}) 308 (58%) patients that had PCC≥0.80 in step one (similar to scenario B), did not receive CSF testing. For the remaining 227 (42%) patients, we added simulated CSF values to identify how such values would impact diagnosis. In 140 patients the cutoff of PCC 0.80 was reached (72 with only positive CSF biomarkers, 46 only negative CSF biomarkers and 22 conflicting CSF biomarkers). When we added the actual CSF results of these patients to calculate DSI and PCC (step three), an additional 71 patients reached our threshold to be diagnosed with sufficient confidence. As a result restricting measurement of CSF to only 26% (140/535), diagnosis with sufficient confidence was reached in 71% of the patients ((308+71)/535). In comparison with the other scenarios, the computerized decision support diagnosed a significantly higher proportion of patients diagnosed with sufficient confidence ([Table 2](#pone.0226784.t002){ref-type="table"}). Of note, the computerized approach even outranks scenario D (all CSF), emphasizing that performing CSF in patients were it is not useful, causes confusing and thus lower confidence in the diagnosis. Furthermore, this approach had a significantly lower proportion of CSF tested compared to scenario C based on AUC.

10.1371/journal.pone.0226784.t002

###### Comparison of the four diagnostic scenarios.

![](pone.0226784.t002){#pone.0226784.t002g}

  Scenario                               Diagnosis with sufficient confidence, PCC≥0.80, n (%)                                                                                CSF performed, n (%)
  -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------
  **A. Computerized decision support**   379 (71%) [\*](#t002fn003){ref-type="table-fn"}^,^[^†^](#t002fn004){ref-type="table-fn"}^,^ [^‡^](#t002fn005){ref-type="table-fn"}   140 (26%)[^§^](#t002fn006){ref-type="table-fn"}
  **B. No CSF**                          308 (58%)                                                                                                                            0 (0%)
  **C. AUC**                             350 (65%)                                                                                                                            295 (55%)
  **D. All CSF**                         348 (65%)                                                                                                                            535 (100%)

AUC: appropriate use criteria according to \[[@pone.0226784.ref033]\], operationalized as a DSI for AD \>0.6, PCC: probability of correct class.

Proportion diagnosed

\*Scenario A vs Scenario B: difference 13%\[[@pone.0226784.ref007]--[@pone.0226784.ref019]\], z = 4.44, p\<0.001

†Scenario A vs Scenario C: difference 6% \[0.4--12\], z = 2.104, p = 0.035

‡Scenario A vs Scenario D: difference 6%\[0.4--12\], z = 2.104, p = 0.035; Proportion CSF performed

§Scenario A vs Scenario C: difference -29% \[--35 ----23\], z = -9.662, p\<0.001

Groups comparison computerized decision support {#sec019}
-----------------------------------------------

When we used the computerized decision support (scenario A, [Fig 1A](#pone.0226784.g001){ref-type="fig"}), we can discern different groups. [Table 3](#pone.0226784.t003){ref-type="table"} shows the baseline characteristics of these different groups. In the largest group 1, patients already had PCC≥0.80 using neuropsychology, MRI and NPO. This group contained mainly controls and patients with a clear clinical profile, i.e. large difference between the highest and second-highest DSI. In group 2, CSF was not helpful as PCC remained \<0.80 also after adding simulated CSF values. This group consisted mainly of AD patients, yet with more WMH and a small difference to the second-highest DSI, indicating high probability of comorbid neuropathology. In group 3 CSF was helpful as PCC increased from \<0.80 to ≥0.80 by adding simulated CSF, and was ≥0.80 also after adding the actual CSF values (a diagnosis could be made). This group contained mainly FTD and AD patients, where especially tau and p-tau were more abnormal. Finally, in group 4 PCC increased from \<0.80 to ≥0.80 by adding simulated CSF, but remained \<0.80 when adding the actual CSF values. Patients in group 4 seemed to have multiple underlying neuropathology, with higher tau and more WMH, and a smaller difference with the second-highest DSI.

10.1371/journal.pone.0226784.t003

###### Patient groups based on computerized decision support (matching [Fig 1A](#pone.0226784.g001){ref-type="fig"}).

![](pone.0226784.t003){#pone.0226784.t003g}

                                               Directly diagnosed   CSF not useful   Diagnosis based on CSF   Not diagnosed   Group wise comparison
  -------------------------------------------- -------------------- ---------------- ------------------------ --------------- -----------------------
  **Female, n (%)**                            164 (53)             31 (36)          34 (48)                  33 (48)         p = 0.036
  **Age, in years**                            64 ± 8               66 ± 8           65 ± 8                   67 ± 8          p = 0.0045
  **APOE e4 carrier, n (%)**                   150 (55)             34 (43)          30 (47)                  38 (66)         p = 0.046
  **MMSE**                                     24 ± 5               25 ± 4           22 ± 4                   22 ± 5          p\<0.001
  ***MRI***                                                                                                                   
  **cMTA right**                               1.1 ± 1.0            1.1 ± 1.0        1.4 ± 0.8                1.4 ± 0.8       p\<0.001
  **cMTA left**                                1.1 ± 1.1            1.2 ± 1.1        1.5 ± 1.1                1.6 ± 1.0       p = 0.0061
  **cGCA**                                     0.9 ± 0.9            0.9 ± 0.8        1.4 ± 0.8                1.3 ± 0.8       p\<0.001
  **WMH, ml**                                  7.3 ± 16.5           9.1 ± 10.9       3.9 ± 4.4                7.2 ± 9.8       p = 0.127
  **AD similarity scale**                      0.5 ± 0.2            0.5 ± 0.1        0.6 ± 0.1                0.6 ± 0.1       p\<0.001
  **Anterior Posterior index**                 -0.1 ± 1.5           -0.4 ± 1.5       -0.3 ± 1.2               -0.6 ± 1.3      p = 0.066
  ***CSF***                                                                                                                   
  **AB42, pg/ml**                              737 ± 300            696 ± 296        653 ± 276                619 ± 251       p = 0.0074
  **Total tau, pg/ml**                         485 ± 365            485 ± 315        667 ± 399                554 ± 380       p = 0.0018
  **P- tau, pg/ml**                            65 ± 36              65 ± 32          87 ± 45                  69 ± 34         p\<0.001
  ***Clinical diagnosis***                                                                                                    p\<0.001
  **Control, n (%)**                           109 (78)             25 (18)          2 (1)                    3 (2)           
  **AD, n (%)**                                134 (47)             42 (15)          55 (19)                  55 (19)         
  **FTD, n (%)**                               44 (54)              15 (18)          13 (16)                  10 (12)         
  **VaD, n (%)**                               21 (75)              5 (18)           1 (4)                    1 (4)           
  **Difference with second DSI without CSF**   0.32 ± 0.09          0.08 ± 0.05      0.11 ± 0.05              0.09 ± 0.04     p\<0.001
  **AUC+ (DSI for AD\>0.6), n (%)**            138 (45)             22 (25)          67 (94)                  68 (99)         p\<0.001

AD: Alzheimer´s disease, FTD: Frontotemporal dementia, VAD: Vascular dementia, MMSE: Mini-Mental state Examination, cMTA: computed medial temporal lobe atrophy scale (0--4), derived from volume of hippocampus and volume of inferor lateral ventricle, cGCA: computed global cortical atrophy scale (0--3), derived from concentration of cortical grey matter using voxel based morphometry, WMH: volume of white matter hyperintensities, AD similarity scale:based on hippocampus ROI, Anterior posterior index: weighted ratio of volumes of the frontal/temporal lobes and parietal/occipital lobes. MRI volumes are adjusted for head size. AB42: beta amyloid 1--42; p-tau: tau phosphorylated at threonine 181. Difference with second DSI without CSF: difference between the two most similar diagnostic groups (first and second DSI), AUC+: number of patients fulfilling appropriate use criteria according to \[[@pone.0226784.ref033]\], operationalized as a DSI for AD \>0.6.

Data are presented as mean ± SD, unless otherwise specified

Nearly all patients in groups 3 and 4 were considered appropriate for CSF following the AUC, showing that our computer-supported decision does not result in a risk of missing patients who would actually have benefited from CSF. In addition, 45% of the patients in group 1 and 30% of the patients in group 2 were considered eligible for CSF testing according to AUC. Yet our computerized decision support predicted that additional CSF testing would not yield additional diagnostic accuracy.

Different PCC cut-offs {#sec020}
----------------------

For the current manuscript, we arbitrarily defined an accurate diagnosis as PCC≥0.80. To circumvent this inherent arbitrariness, we repeated our analyses for different PCC cutoffs. [Fig 2](#pone.0226784.g002){ref-type="fig"} shows the share of patients with CSF tested and the share of patients diagnosed for different PCC cutoffs, comparing the four diagnostic scenarios: the computerized decision support, no CSF, AUC and CSF for all patients. Overall, a higher PCC cutoff resulted in a lower number of diagnosed patients. Independent of PCC cutoff, applying no CSF resulted in the smallest share of patients diagnosed, while the stepwise approach gave the largest share of patients diagnosed with CSF tested in max 26.5% patients.

![Share of patients diagnosed and share of patients with CSF measured for different probability of correct class cutoffs, comparing computerized decision support, no CSF, AUC and CSF for all patients.\
Blue: proportion of patients diagnosed, Red: proportion of patients with CSF measured, PCC: probability of correct class. Solid lines show results for the computerized decision support ([Fig 1A](#pone.0226784.g001){ref-type="fig"}), dotted lines show results for using no CSF, but only neuropsychology, MRI and APOE ([Fig 1B](#pone.0226784.g001){ref-type="fig"}), dashed dotted lines show results for AUC ([Fig 1C](#pone.0226784.g001){ref-type="fig"}) and dashed lines using all data ([Fig 1D](#pone.0226784.g001){ref-type="fig"}).](pone.0226784.g002){#pone.0226784.g002}

Regardless of PCC cutoff, the accuracy of the four different approaches remained comparable (see [S1 Fig](#pone.0226784.s002){ref-type="supplementary-material"}) demonstrating that the stepwise approach does not compromise accuracy.

Visualization of computerized decision support {#sec021}
----------------------------------------------

To enable clinicians to use this method in daily practice, we have visualized the computerized decision support in [Fig 3](#pone.0226784.g003){ref-type="fig"}. Using the DSI classifier, clinicians select the PCC threshold (default PCC≥0.80) and simulate positive and negative CSF biomarkers. The resulting change in PCC can then support the clinician to refrain from or embark on CSF testing. In [Fig 3](#pone.0226784.g003){ref-type="fig"}, two examples of the visualization for clinical use are shown. For patient A, the clinician chose the default PCC cutoff of 0.80. When using only neuropsychology, MRI and APOE data, the highest DSI was obtained for AD with a 72% probability of correct diagnosis. When adding simulated CSF, PCC increased to 0.89 (AD-like CSF), resulting also in a higher DSI for AD. When CSF would be negative, PCC also increased to 0.86 resulting in higher DSI for FTD. As the simulated CSF values resulted in a PCC above the cutoff of 0.80, the suggested advice by the tool is that "CSF measurement is considered potentially useful". Following this advice, the results of the actually performed CSF testing are shown in the bottom panel. The actual CSF biomarker results were AD-like, resulting in a clinical AD diagnosis with 91% probability of correct diagnosis. For patient B, however, simulating only negative CSF increased the PCC above 0.80. And indeed, actual CSF ruled out AD and indicated FTD as the most probable diagnosis. This was also the clinical diagnosis.

![Examples of visualization simulated CSF for clinical use.\
PCC: probability of correct class, AD: Alzheimer´s disease, FTD: Frontotemporal dementia, VAD: Vascular dementia, CN: control. For patient A both simulated positive and negative CSF resulted in an increase of PCC. Adding actual CSF confirmed the AD diagnosis. For patient B simulated negative CSF increased the PCC. Adding actual CSF ruled out AD and indicated FTD as the most probable diagnosis.](pone.0226784.g003){#pone.0226784.g003}

Discussion {#sec022}
==========

Although relevant for diagnosing and excluding AD, it remains unclear in which patients applying CSF biomarkers has most added value. This study showed that a data-driven, individualized approach, simulating CSF outcome before embarking on actual CSF testing, can help in identifying those patients in whom CSF biomarkers are most likely to contribute to a more accurate diagnosis. Recommending CSF testing in only one quarter of patients, our computerized decision support led to a diagnosis with sufficient confidence in 71% of the patients. By contrast, in the three other scenarios (CSF in none, based on AUC or CSF in all) less patients were diagnosed with sufficient confidence. By visualizing the effect of simulated CSF ([Fig 3](#pone.0226784.g003){ref-type="fig"}) on the probability of correct class (PCC), clinicians can be supported in making a conscious decision in ordering additional biomarker testing.

Neurodegenerative disorders in general and AD in specific, are increasingly considered as biologically defined diseases. Current guidelines and diagnostic criteria therefore emphasize the use of biomarkers \[[@pone.0226784.ref002], [@pone.0226784.ref004]\]. By using these biomarkers, the clinician can either confirm or rule out underlying AD. Yet, clinicians do not often apply CSF biomarkers \[[@pone.0226784.ref036]\]. The appropriate use criteria (AUC) which have been proposed as a guideline, are generally worded and challenging to translate to clinical practice \[[@pone.0226784.ref006]\]. In our study, more than half of the patients would be selected for CSF measurement based on fulfillment of the AUC. In addition to specifying criteria, the AUC further mention that the clinician should estimate 'how CSF biomarkers might contribute to the diagnosis and clinical decision making' \[[@pone.0226784.ref006]\]. Operationalization of this statement is difficult. Tools are therefore needed in search for an answer on the question 'which patient benefits most from CSF?'. To select patients for amyloid measurement, previous studies have aimed to 'predict' amyloid positivity in controls and patients with AD \[[@pone.0226784.ref037]--[@pone.0226784.ref040]\]. Yet a clinician requires information on how knowledge on amyloid predicts clinical outcome. We added to these studies by using a data-driven approach including not only controls and AD, but also patients with VaD and FTD, and simulated AB42, tau and p-tau values to guide decision making.

In the computerized decision support approach, PCC is first calculated using only neuropsychology, MRI and APOE data. If the clinician considers the PCC (= the confidence in the correct diagnosis) high enough, no additional testing is needed. This was frequently the case for controls and VaD \[[@pone.0226784.ref011]\]. When the PCC is too low, simulated normal or AD-like CSF values are added, enabling the clinicians to decide whether the change in PCC is enough for them to order additional testing. If the PCC remains low, the clinician could use this information to refrain from embarking on CSF testing, which would only yield unnecessary costs without improving diagnostic accuracy. Contrariwise the clinician could take other further steps to improve diagnostic certainty, e.g. genetic screening or FDG-PET. One could imagine that comparable approaches would be developed for these other diagnostic tests.

As an example, we used PCC≥0.80 as a cut-off. There is however some inherent arbitrariness to the cut-off of diagnostic certainty. It is for example unclear what level of certainty is acceptable in clinical practice. Also, clinicians may value the PCC differently, and may want to use less or more stringent cut-off values. This is why we repeated our analyses for a wide range of cut-offs, resulting in [Fig 2](#pone.0226784.g002){ref-type="fig"}. Independent of PCC cut-off, the results remained largely similar: using estimated CSF values to support the choice to embark on testing, helps to reduce costs (smaller proportion CSF testing) while improving diagnostic certainty.

An often mentioned, and important limitation of data-driven decision support systems is that they require multiple pieces of data that are not readily available to the clinician, or that the models are too complex which limit their clinical footprint. In order for clinical decision support tools to be implemented in clinical practice, they should have an understandable basis and be intuitive (i.e. not a complex black box), time efficient, and assist rather than replace the clinician \[[@pone.0226784.ref007]\]. Our stepwise approach meets all these requirements; well-known CSF values are simulated in a simple way and the tool provides a suggestion on the usefulness of CSF testing. We used the DSI classifier, an existing, validated machine learning algorithm \[[@pone.0226784.ref010], [@pone.0226784.ref012]\]. The DSI classifier has a graphical counterpart which makes interpretation of results to clinicians more transparent (an example is shown in [Fig 3](#pone.0226784.g003){ref-type="fig"}), tolerates missing data (no imputation needed), and gives information about the confidence of the classification.

Furthermore, we used data of three different memory clinic cohorts, warranting a heterogeneous sample. All patients came to the memory clinic seeking medical help; our data thus reflects real-life, clinical patients. In each clinic, patients were diagnosed using a standard clinical workup, and we were able to use measures that overlapped. CSF analyses were performed in three different laboratories, yet we found no significant differences in values between the three centers. MRI scans were acquired on systems with different field strengths, but the automatic analyses of these scans were all performed by the same software \[[@pone.0226784.ref009]\].

Some limitations also warrant discussion. First, we categorized patients as having single pathologies, while on average 20--40% patients have in fact multiple pathologies, contributing to their syndrome of dementia \[[@pone.0226784.ref041]\]. This is probably also the case in our sample, as can be seen in diagnostic group 4, described in [Fig 1](#pone.0226784.g001){ref-type="fig"} and [Table 3](#pone.0226784.t003){ref-type="table"}. Here we see a smaller difference with the second DSI (and subsequently a low PCC), suggesting mixed pathology. Second, a limitation could be the use of SCD as controls. However, if SCD is indeed an enriched population, then the ability of our computerized decision support approach to select the correct patient for CSF testing would be underestimated, and would even be better if 'healthy controls' were used. In fact, clinical practice is not about comparing AD patients with healthy controls, but on the differential diagnosis. As SCD patients do seek help for their complaints, they also reflect daily clinical practice, where clinical decision support systems should work.Third, we simulated positive or negative CSF biomarkers and did not include amyloid-PET. This would hamper use of our computerized approach, for example, in the United States, where amyloid-PET is more frequently used than CSF. However, we know CSF correlates strongly with amyloid-PET, especially when both AB42 and tau have been used (as we did here) \[[@pone.0226784.ref042]\]. Research replicating this study using PET instead, would be a useful addition to this work. Another interesting field for future work is MCI. CSF is a known predictor of progression from MCI to dementia; applying a stepwise approach might be helpful in guiding clinicians also in this challenge \[[@pone.0226784.ref043]\]. Finally, future studies should evaluate this approach in a prospective design.

The diagnostic routine for AD is very suitable for shared decision making as there is typically more than one reasonable option to choose, such as either perform or not perform additional CSF testing \[[@pone.0226784.ref044]\]. In shared decision making, the clinician and patient decide together which care plan best fits with individual preferences and needs \[[@pone.0226784.ref045]\]. An important aspect of shared decision making is that appropriate expectations are set, and recognize that the decision for or against biomarker testing is a highly individualized decision that warrants a shared decision making approach \[[@pone.0226784.ref046]\]. However, previous research showed that informing patients on diagnostic testing in general was not standard in the memory clinic \[[@pone.0226784.ref036], [@pone.0226784.ref044], [@pone.0226784.ref047]\]. The current paper helps clinicians to appreciate whether biomarkers are potentially useful for a specific patient. This information could then be the topic of a dialogue between clinician and patient/caregiver before actually ordering the test. This in turn aids the clinicians in appropriate expectation setting before embarking on biomarker testing.

In conclusion, we showed that computerized decision support can guide clinicians in who will benefit from CSF and who will not. This resulted in an optimized diagnosis that is at the same time cost-effective. Clinicians can thus order CSF applying a data-driven, individualized approach. By visualizing the effect of simulated CSF on diagnostic certainty, clinicians can be supported in making a weighted decision in ordering additional biomarker testing.
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I still have some questions for this work.
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VBM was conducted by which software and whether to eliminate the effect of volume of cranial cavity. Please specify the processes which would help others to verified the results.
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Reply: You are of course correct in stating that the chosen CSF biomarkers are all AD-related markers. In clinical practice these are the CSF biomarkers that clinicians can use for detecting AD pathology during life; CSF biomarkers for FTD and VaD unfortunately have not been developed yet. Nonetheless, CSF biomarkers for AD may still be useful in the differential diagnosis of FTD and VaD. In clinical practice the clinician is faced with a differential diagnostic dilemma's for all his/her patients. It is thus not about 'controls versus AD', but about 'this type of dementia or that type of dementia'. A tool that supports clinicians in ordering CSF biomarkers in daily practice, should thus be able to cope with this differential diagnostic dilemma. Especially since there can be a broad overlap in clinical symptoms in AD, FTD and VaD. Negative AD-biomarkers increase the likelihood of another underlying pathology, and may in turn help the clinician with this differential diagnostic dilemma. Our computerized decision approach aids for all diagnostic groups, as can be seen in table 3, pointing out both patients in which CSF is not needed and patient in which CSF is useful. For this group with different types of dementia, reflecting clinical practice, we need CSF in only 1 out of 4 patients, without compromising diagnostic accuracy.

Reviewer \#2: 1) Line 131, the reference associated with RAVLT needs to be revised.

Reply: We apologize for this mistake and added the correct reference (L132).

2\) Line 134, in \[21\] the paper presents different verbal fluency tests, why the choice of animals ? and did the author try with other categories to see if this leads to different findings ?

Reply: Thank you for this interesting suggestion. One can definitely argue for example letter fluency, and the difference between letter and animal fluency, can be very indicative. In our dataset (which we used retrospectively) we only had information on animal fluency, not on other categories. However we were able to construct a brief standardized test battery that contains widely used tests, and is thus representative for clinical practice, where our tool should work.

3\) Line 157, incorrect citation \[9\], please provide the original references, I suppose the author needs to cite this paper in his/her case; Lötjönen J., Wolz R., Koikkalainen J., Thurfjell L., Waldemar G., Soininen H., Rueckert D. Fast and robust multi-atlas segmentation of brain magnetic resonance images. NeuroImage. 2010;49(3):2352--2365

Reply: We added this reference to the revised manuscript (L158).

4\) Line 247, in table 1, not all the characteristics are available for all patients, how did the author deal with missing information ? How confident is he/she about their effect on the results.

Reply: Indeed, information on APOEe4 status and several cognitive tests is missing in a small proportion of the patients. Due to the design of DSI, there is no need to impute data or exclude cases with incomplete data, as only available data are used. Furthermore, we repeated our analysis with whole cases only, and found no relevant change. We added a remark on this to the paragraph on the DSI in the Methods section and included a reference to Tolonen Front Aging Neurosciene 2018 (ref 10), were this is explained in detail (L187-188).

5\) Line 265, it is unclear to me how the author has simulated the CSF values.

Reply: We simulated the CSF values by taking age- and sex-normalized median AB42, tau and p-tau values of the AD group (=positive CSF values) and by taking age- and sex-normalized median AB42, tau and p-tau values of the SCD group (=negative CSF values). This age- and sex normalization is done in the same way as for the MRI markers (see ref 31). We described this in the paragraph on 'Simulated CSF to guide clinical decision making' in the Methods section and added reference 31 to the text (L216). Hopefully this clarifies the used method.

6\) Line 276, table2 , I would appreciate if the author interprets and explains why scenario A had higher rate than scenario D.

Reply: Thank you for the opportunity to elaborate on this interesting finding. Scenario A results in a higher proportion of patients diagnosed with sufficient probability as compared to the other scenario's (including scenario D), while proportion of performed CSF is much lower. This shows exactly why tools like develop in our study are needed; CSF testing is clearly only useful when it increases the confidence in the diagnosis. One can imagine that borderline CSF values or in case of multiple pathologies, adding CSF values only confuses and leads to lower proportion of diagnosed patients. This can also be seen in f.e. group 2 and group 4 (as shown in Table 3) were CSF did not help. We added a sentence on this to the section above Table 2 (L276-278).

7\) According to the figure in the supplementary notes, the higher DSI/delta_DSI the closer PCC to 1. Hence, the higher PCC the better for the diagnosis, how does the author explain that for values larger than 0.8 the accuracy of diagnosis decreased (line 335).

Reply: You are correct in assuming that the PCC correlates to the accuracy of the diagnosis. As can be seen in S1 Fig, the accuracy (as indicated by the black line) increases with increasing PCC, also for values larger than 0.8. Setting the cut-off for a 'certain' diagnosis higher, results in less patients diagnosed. This can be seen in Fig 2: the proportion of diagnosed patients decreases with increasing PCC, since fewer patients while have a very high PCC leading to a smaller proportion of patients. Please also note that in this line we refer to the number of patients diagnosed, and not to the accuracy. We hope this explains both Fig 2 and S1 Fig.
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